• Carlton Dampier, Petra LeBeau, Seungshin Rhee, Susan Lieff, Karen Kesler, Samir Ballas, Zora Rogers, Winfred Wang, and Comprehensive Sickle Cell Centers (CSCC) Clinical Trial Consortium (CTC) Site Investigators.
• Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia 30322, USA. cdampie@emory.edu
• Am. J. Hematol. 2011 Feb 1;86(2):203-5.

AbstractAdults with Sickle Cell Disease (SCD) experience multiple disease-related complications, but few studies have examined relationships between these events and health-related quality of life (HRQOL). We determined the number and type of previous or co-occurring SCD-related complications and their reported HRQOL in a cohort of 1,046 adults from the Comprehensive Sickle Cell Centers (CSCC). Participants had a median age of 28.0 years (48% male, 73% SS or Sβ⁰ thalassemia) and had experienced several SCD-related complications (mean 3.8 ± 2.0), which were influenced by age, gender, and hemoglobinopathy type (P < 0.0001). In multivariate models, increasing age reduced all SF-36 scales scores (P < 0.05) except mental health, while female gender additionally diminished physical function and vitality scale scores (P < 0.01). Of possible complications, only vaso-occlusive crisis, asthma, or avascular necrosis diminished SF-36 scale scores. Chronic antidepressants usage predominantly diminished scores on bodily pain, vitality, social functioning, emotional role, and mental health scales, whereas chronic opioid usage diminished all scale scores (P < 0.01). Our study documents substantial impairment of HRQOL in adults with SCD that was influenced by only a few of many possible medical complications. It suggests that more effective treatments of persistent pain and depression would provide the largest HRQOL benefit.

45 keywords...

hide…